


exo-IWR-1

Cat. No.:	HY-108437		
CAS No.:	1127442-87-8		
Molecular Formula:	C ₂₅ H ₁₉ N ₃ O ₃		
Molecular Weight:	409.44		
Target:	Wnt		
Pathway:	Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 2 mg/mL (4.88 mM; ultrasonic and warming and heat to 60°C)

Caution: Product has not been fully validated for medical applications. For research use only.

Solvent	1 mg	5 mg	10 mg
Concentration			
1 mM	2.4424 mL	12.2118 mL	24.4236 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

exo-IWR-1, an inactive stereoisomer of Endo-IWR-1, is a negative control of IWR-1 (HY-12238). IWR-1 is a tankyrase inhibitor which inhibits Wnt/ β -catenin signaling pathway^{[1][2]}.

In Vitro

exo-IWR-1 (10 μ M) does not influence the number of 293T cells infected with bunyaviruses^[1].
 Exo-IWR-1 had no effect on RVFV MP12-GFP infection when cells were either pretreated or treated 1 hpi^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Brooke Hamion, et al. Genome-wide RNA Interference Screen Identifies Novel Drug Targets for Rift Valley Fever Virus That Minimize the Potential for Drug Resistance.

[2]. Brooke Harmon, et al. A Genome-Wide RNA Interference Screen Identifies a Role for Wnt/ β -Catenin Signaling during Rift Valley Fever Virus Infection. J Virol. 2016 Jul 27;90(16):7084-7097.